miR-10b and miR-223-3p in serum microvesicles signal progression from prediabetes to type 2 diabetes.
Biomarker
Diagnosis
MicroRNA
Microvesicle
Prediabetes
Progression
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
08
08
2019
accepted:
03
10
2019
pubmed:
14
11
2019
medline:
15
12
2020
entrez:
14
11
2019
Statut:
ppublish
Résumé
Type 2 diabetes frequently remains undiagnosed for years, whereas early detection of affected individuals would facilitate the implementation of timely and cost-effective therapies, hence decreasing morbidity. With the intention of identifying novel diagnostic biomarkers, we characterized the miRNA profile of microvesicles isolated from retroactive serum samples of normoglycemic individuals and two groups of subjects with prediabetes that in the following 4 years either progressed to overt diabetes or remained stable. We profiled miRNAs in serum microvesicles of a selected group of control and prediabetic individuals participating in the PREDAPS cohort study. Half of the subjects with prediabetes were diagnosed with diabetes during the 4 years of follow-up, while the glycemic status of the other half remained unchanged. We identified two miRNAs, miR-10b and miR-223-3p, which target components of the insulin signaling pathway and whose ratio discriminates between these two subgroups of prediabetic individuals at a stage at which other features, including glycemia, are less proficient at separating them. In global, the profile of miRNAs in microvesicles of prediabetic subjects primed to progress to overt diabetes was more similar to that of diabetic patients than the profile of prediabetic subjects who did not progress. We have identified a miRNA signature in serum microvesicles that can be used as a new screening biomarker to identify subjects with prediabetes at high risk of developing diabetes, hence allowing the implementation of earlier, and probably more effective, therapeutic interventions.
Identifiants
pubmed: 31721085
doi: 10.1007/s40618-019-01129-z
pii: 10.1007/s40618-019-01129-z
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
MIRN10 microRNA, human
0
MIRN223 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-459Subventions
Organisme : European Foundation for the Study of Diabetes
ID : Lilly 2013
Organisme : Novartis Farmacéutica
ID : N/A
Organisme : CIBERDEM
ID : N/A
Références
Cho NH, Shaw JE, Karuranga S et al (2018) IDF diabetes atlas. Diabetes Res Clin Pract 138:271–281. https://doi.org/10.1016/j.diabres.2018.02.023
doi: 10.1016/j.diabres.2018.02.023
pubmed: 29496507
Soriguer F, Goday A, Bosch-Comas A et al (2012) Prevalence of diabetes mellitus and impaired glucose regulation in Spain: Di@bet.es study. Diabetologia 55:88–93. https://doi.org/10.1007/s00125-011-2336-9
doi: 10.1007/s00125-011-2336-9
pubmed: 21987347
Mata-Cases M, Casajuana M, Franch-Nadal J et al (2016) Direct medical costs attributable to type 2 diabetes: a population-based study in Catalonia, Spain. Eur J Health Econ 17:1001–1010. https://doi.org/10.1007/s10198-015-0742-5
doi: 10.1007/s10198-015-0742-5
pubmed: 26542160
Müller G (2012) Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes Metab Syndr Obes Targets Ther 5:247–282. https://doi.org/10.2147/DMSO.S32923
doi: 10.2147/DMSO.S32923
Pirola L, Balcerczyk A, Okabe J, El-Osta A (2010) Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 6:665–675. https://doi.org/10.1038/nrendo.2010.188
doi: 10.1038/nrendo.2010.188
pubmed: 21045787
Párrizas M, Novials A (2016) Circulating microRNAs as biomarkers for metabolic disease. Best Pract Res Clin Endocrinol Metab 30:591–601. https://doi.org/10.1016/j.beem.2016.08.001
doi: 10.1016/j.beem.2016.08.001
pubmed: 27923453
Bartel DP (2018) Metazoan microRNAs. Cell 173:20–51
doi: 10.1016/j.cell.2018.03.006
pubmed: 29570994
pmcid: 6091663
Castaño C, Novials A, Párrizas M (2019) Exosomes and diabetes. Diabetes Metab Res Rev 2019:e3107. https://doi.org/10.1002/dmrr.3107
doi: 10.1002/dmrr.3107
Párrizas M, Brugnara L, Esteban Y et al (2015) Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J Clin Endocrinol Metab 100:E407–E415. https://doi.org/10.1210/jc.2014-2574
doi: 10.1210/jc.2014-2574
pubmed: 25532038
Thomou T, Mori MA, Dreyfuss JM et al (2017) Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 542:450–455. https://doi.org/10.1038/nature21365
doi: 10.1038/nature21365
pubmed: 28199304
pmcid: 5330251
Ying W, Riopel M, Bandyopadhyay G et al (2017) Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 171:372–384. https://doi.org/10.1016/j.cell.2017.08.035
doi: 10.1016/j.cell.2017.08.035
pubmed: 28942920
Castaño C, Kalko S, Novials A, Párrizas M (2018) Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci 115:12158–12163. https://doi.org/10.1073/pnas.1808855115
doi: 10.1073/pnas.1808855115
pubmed: 30429322
pmcid: 6275521
Diaz-Redondo A, Giraldez-Garcia C, Carrillo L et al (2015) Modifiable risk factors associated with prediabetes in men and women: cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS). BMC Fam Pract 16:5. https://doi.org/10.1186/s12875-014-0216-3
doi: 10.1186/s12875-014-0216-3
pubmed: 25609029
pmcid: 4316391
Franch-Nadal J, Caballeria L, Mata-Cases M et al (2018) Fatty liver index is a predictor of incident diabetes in patients with prediabetes: PREDAPS study. PLoS One 13:1–17. https://doi.org/10.1371/journal.pone.0198327
doi: 10.1371/journal.pone.0198327
Giráldez-García C, Franch-Nadal J, Sangrós FJ et al (2018) Adiposity and diabetes risk in adults with prediabetes: heterogeneity of findings depending on age and anthropometric measure. Obesity 26:1481–1490. https://doi.org/10.1002/oby.22256
doi: 10.1002/oby.22256
pubmed: 30070055
Bedogni G, Bellentani S, Miglioli L et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. https://doi.org/10.1186/1471-230x-6-33
doi: 10.1186/1471-230x-6-33
pubmed: 17081293
pmcid: 1636651
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Tirosh A, Shai I, Tekes-Manova D et al (2005) Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 353:1454–1462. https://doi.org/10.1056/NEJMoa050080
doi: 10.1056/NEJMoa050080
pubmed: 16207847
Wang K, Yuan Y, Cho JH et al (2012) Comparing the microRNA spectrum between serum and plasma. PLoS One 7:e41561. https://doi.org/10.1371/journal.pone.0041561
doi: 10.1371/journal.pone.0041561
pubmed: 22859996
pmcid: 3409228
Gong Q, Gregg EW, Wang J et al (2011) Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: China Da Qing Diabetes Prevention Outcome Study. Diabetologia 54:300–307. https://doi.org/10.1007/s00125-010-1948-9
doi: 10.1007/s00125-010-1948-9
pubmed: 21046360
Lindstrom J, Peltonen M, Eriksson JG et al (2013) Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study. Diabetologia 56:284–293. https://doi.org/10.1007/s00125-012-2752-5
doi: 10.1007/s00125-012-2752-5
pubmed: 23093136
He Y, Ding Y, Liang B et al (2017) A systematic study of dysregulated microRNA in type 2 diabetes. Int J Mol Sci 18:456. https://doi.org/10.3390/ijms18030456
doi: 10.3390/ijms18030456
pmcid: 5372489
Liang YZ, Li JJH, Xiao HB et al (2018) Identification of stress-related microRNA biomarkers in type 2 diabetes: a systematic review and meta-analysis. J Diabetes. https://doi.org/10.1111/1753-0407.12643
doi: 10.1111/1753-0407.12643
pubmed: 30203544
Lund AH (2010) miR-10 in development and cancer. Cell Death Differ 17:209–214. https://doi.org/10.1038/cdd.2009.58
doi: 10.1038/cdd.2009.58
pubmed: 19461655
Zhao X, Chen Z, Zhou Z et al (2019) High-throughput sequencing of small RNAs and analysis of differentially expressed microRNAs associated with high-fat diet-induced hepatic insulin resistance in mice. Genes Nutr 14:6. https://doi.org/10.1186/s12263-019-0630-1
doi: 10.1186/s12263-019-0630-1
pubmed: 30820263
pmcid: 6379981
Herrera BM, Lockstone HE, Taylor JM et al (2010) Global miRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 53:1099–1109. https://doi.org/10.1007/s00125-010-1667-2
doi: 10.1007/s00125-010-1667-2
pubmed: 20198361
pmcid: 2860560
Wen D, Qiao P, Wang L (2015) Circulating miR-223 as a potential biomarker for obesity. Obes Res Clin Pract 9:398–404. https://doi.org/10.1016/j.orcp.2015.01.006
doi: 10.1016/j.orcp.2015.01.006
pubmed: 25842981
Ye D, Zhang T, Lou G, Liu Y (2018) Role of miR-223 in the pathophysiology of liver diseases. Exp Mol Med 50:128. https://doi.org/10.1038/s12276-018-0153-7
doi: 10.1038/s12276-018-0153-7
pmcid: 6158210
Aziz F (2016) The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Immunol 303:1–6. https://doi.org/10.1016/j.cellimm.2016.04.003
doi: 10.1016/j.cellimm.2016.04.003
pubmed: 27129807
Hay N (2011) Akt isoforms and glucose homeostasis. Trends Endocrinol Metab 22:66–73. https://doi.org/10.1016/j.tem.2010.09.003
doi: 10.1016/j.tem.2010.09.003
pubmed: 20947368
Fabre A, Marchal S, Barlogis V et al (2019) Clinical aspects of STAT3 gain-of-function germline mutations. J Allergy Clin Immunol Pract 7:1958–1969. https://doi.org/10.1016/j.jaip.2019.02.018
doi: 10.1016/j.jaip.2019.02.018
pubmed: 30825606
Kung C-P, Murphy ME (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231:R61–R75. https://doi.org/10.1530/JOE-16-0324
doi: 10.1530/JOE-16-0324
pubmed: 27613337
pmcid: 5148674
Moldovan L, Batte KE, Trgovcich J et al (2014) Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 18:371–390. https://doi.org/10.1111/jcmm.12236
doi: 10.1111/jcmm.12236
pubmed: 24533657
pmcid: 3943687
Venturella M, Carpi FM, Zocco D (2019) Standardization of blood collection and processing for the diagnostic use of extracellular vesicles. Curr Pathobiol Rep. https://doi.org/10.1007/s40139-019-00189-3
doi: 10.1007/s40139-019-00189-3
Blondal T, Jensby Nielsen S, Baker A et al (2013) Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59:164–169. https://doi.org/10.1016/j.ymeth.2012.09.015
doi: 10.1016/j.ymeth.2012.09.015